Equities analysts predict that Nevro Corp (NYSE:NVRO) will report earnings per share (EPS) of ($0.29) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Nevro’s earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.03). Nevro reported earnings per share of ($0.21) during the same quarter last year, which indicates a negative year over year growth rate of 38.1%. The company is scheduled to announce its next earnings report on Monday, November 5th.
According to Zacks, analysts expect that Nevro will report full-year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($0.95). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.50) per share, with EPS estimates ranging from ($1.05) to $0.19. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Nevro.
Nevro (NYSE:NVRO) last released its quarterly earnings data on Thursday, August 2nd. The medical equipment provider reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.04). Nevro had a negative net margin of 10.68% and a negative return on equity of 15.84%. The business had revenue of $96.10 million for the quarter, compared to the consensus estimate of $96.10 million. During the same quarter last year, the firm earned ($0.40) EPS. The company’s revenue for the quarter was up 23.2% on a year-over-year basis.
Several research analysts have weighed in on the company. Canaccord Genuity reduced their target price on Nevro from $110.00 to $102.00 and set a “buy” rating for the company in a research note on Tuesday, May 8th. Morgan Stanley reduced their target price on Nevro from $88.00 to $65.00 and set an “equal weight” rating for the company in a research note on Tuesday, July 17th. ValuEngine downgraded Nevro from a “hold” rating to a “sell” rating in a research note on Tuesday, May 8th. Northland Securities downgraded Nevro from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 8th. Finally, Wells Fargo & Co reduced their target price on Nevro from $84.00 to $62.00 and set a “market perform” rating for the company in a research note on Tuesday, July 17th. Three research analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. Nevro has a consensus rating of “Hold” and a consensus price target of $81.89.
Shares of Nevro traded up $0.72, hitting $64.23, during trading on Friday, Marketbeat Ratings reports. 404,807 shares of the company were exchanged, compared to its average volume of 1,641,840. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -51.38 and a beta of -0.83. Nevro has a fifty-two week low of $35.41 and a fifty-two week high of $94.34. The company has a quick ratio of 6.29, a current ratio of 8.06 and a debt-to-equity ratio of 0.61.
In other news, CFO Andrew H. Galligan sold 7,000 shares of the business’s stock in a transaction on Monday, May 14th. The stock was sold at an average price of $76.14, for a total transaction of $532,980.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.90% of the company’s stock.
Several institutional investors have recently bought and sold shares of NVRO. US Bancorp DE increased its stake in shares of Nevro by 14.3% in the first quarter. US Bancorp DE now owns 5,176 shares of the medical equipment provider’s stock valued at $449,000 after buying an additional 646 shares during the period. Denver Investment Advisors LLC increased its stake in shares of Nevro by 7.0% in the first quarter. Denver Investment Advisors LLC now owns 10,570 shares of the medical equipment provider’s stock valued at $916,000 after buying an additional 689 shares during the period. Xact Kapitalforvaltning AB increased its stake in shares of Nevro by 23.1% in the second quarter. Xact Kapitalforvaltning AB now owns 4,258 shares of the medical equipment provider’s stock valued at $340,000 after buying an additional 800 shares during the period. Rhumbline Advisers increased its stake in shares of Nevro by 3.1% in the second quarter. Rhumbline Advisers now owns 28,525 shares of the medical equipment provider’s stock valued at $2,278,000 after buying an additional 856 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Nevro by 69.7% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,432 shares of the medical equipment provider’s stock valued at $210,000 after buying an additional 999 shares during the period.
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Featured Story: Investing in Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.